But many of the middle-income countries with a high burden of hepatitis C, such as China, Brazil, Ukraine and
Latin America, will continue to be excluded by the terms of voluntary licensing agreements from obtaining Indian generics – unless they pursue compulsory licensing. "
"In the case of hepatitis C treatment, people could take matters into their own hands without waiting for governments.